National Asthma Education and Prevention Program: Summary of 2007 Guidelines for Asthma Management
The Guidelines Emphasize ICSs as Key to Achieving Optimal Asthma Control3
Classification of Severity and Initiating Treatment in Youths ≥12 Years of Age and Adults3
“Daily long-term control medication is recommended for patients who have persistent asthma. The long-term control medication should be one with anti-inflammatory effects. Of the available medications, ICSs are the most effective single agents.”3
- Optimize ICS use before considering combination therapy3
- Long-acting beta2-agonists (LABAs) are not recommended as monotherapy for long-term control of persistent
asthma3
NAEPP Guidelines Support First-Line ICS in Children, Regardless of Asthma Severity
3
“[F]or patients who have asthma not sufficiently controlled with a low-dose ICS alone, the step-up option to increase the ICS dose should be given equal weight to that of the addition of a LABA to ICS.”3
- There is high-quality evidence of the effectiveness of ICSs as initial therapy for children [5 to 11 years of age] with
persistent asthma3
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
- National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; August 2007.
- Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone*: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
080718